BTW I have so many of these turkeys ignored and greyed out I really do not know what they are saying anyway. YMB will serve the longs better if everybody does this so we can focus on information in a more positive light. IMHO
BTW fnsmsft - Your wasting your time trying to explain anything rational to this fiduciarydoozy character. He has his own agenda and it is not positive quite the contrary.
Nov 6–9, 2014 29th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC)
Location: National Harbor, MD
Simple I understand the process for small Biotech's to bring a drug to the market.
Equity financing is part of the process, shareholders have to deal with this and much more. The end game, what will the science provide? Everything leading up to this is secondary. Speculation is not for everyone. Go grind your ax some more.
LOL I sent an email yesterday to our local channel 7 news in our DC area with information on this Ebola. Then this newswire comes out this morning.
How do you figure that? Wagon44 and me are the same in our understanding of the value Bavi presents. Like most positive, optimistic LONGS we based our decisions on our DD
this leads us to a good understanding of the science underlying the trials and so much more. The P2 fiasco clouded things up for many but the fog is lifting. IOMGENE149 how do you come up with these thoughts. Good luck to you sir/madam.
continued.... to increase, especially if you are short and just hoping Big Pharma will have their way like they are used to in the past
I find one thing hard to believe and that is the opportunity of a lifetime is still dangling out there like a carrot for anyone to take advantage if they can see a few of the puzzle pieces
It was also hard for some to believe that Fargo was even a possibility.
It was also hard for some to believe that the FDA would accept the phase IIb NSCLC data and use that data to approve a Phase III
It was also hard for some to believe that the FDA seen such data, good data, even historically good data from the phase IIb, that FAST TRACK was awarded
It was also hard for some to believe that 4 of the top KOL's in the world would see clinical data, that ultimately they are now working with Peregrine Pharmaceuticals
It was also hard for some to believe that little old Peregrine could raise money, in a way, that is not used often...if at all, with other small biotechs and yet they accomplished that easily i selling preferred shares at a price per share of $25
It was also hard for some to believe that Peregrine, with no Big Pharma partner, would be able to open up close to 150 clinical sites for their Phase III
It was also hard for some to believe that there would be "dozens of collaborations.." taking place, all based on PS Targeting, that allows for the return of the body into a much more, homeostatic state via the global biomarker = Myeloid Derived Suppressor Cells which if out of balance... forced the Ph in ones blood out of balance... which forces much more serious events such as cancer to continue, sometimes to metastasize and make it hard to believe for those cancer patients
The KOL's know this, Dr. Rolf Brekken knows this, Peregrine knows this, all the patients treated with Bavituximab and seen the results know this, and even Dr. Jedd Wolchok and Alexander Lisokhin (that have ties to Bristol Myers Squibb) certainly know this...
and here we sit talking about 170,000,000 shares floating ? Funny... we will need at least 1-2 Billion shares just to continue this journey and when all is said and done... we will have about 4-8 Billion shares floating.
Please don't try to connect too many puzzle pieces too fast, it may cost ones blood sugar..
True that, If no one is interested in those POST on this message board and it is not assisting anyone then I'll stop. Not sure if that is the case as of this moment.
Novartis ($NVS) is hitching a few of its cancer drugs to Bristol-Myers Squibb's ($BMY) closely watched clinical wagon for nivolumab (Opdivo). The pharma giant says it is now prepping new studies that will test how well three of its oncology drugs--the experimental INC280 and EGF816 and the newly approved ALK inhibitor Zykadia--do when combined with the PD-1 drug nivolumab in a joint attack on non-small cell lung cancer.
Underscoring Bristol-Myers' pedal-to-the-metal approach to developing new immuno-oncology combination therapies, the big biotech also announced plans today to collaborate with investigators at MD Anderson in Houston on up to 10 trials that will match nivolumab and Yervoy with a slate of the company's early-stage cancer drugs. Those studies will look to fast-track internal efforts on acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndrome and myelofibrosis.
"Preclinical data suggests that combining molecularly targeted agents with immunotherapies such as nivolumab may have synergistic effects and lead to better outcomes for patients," said Dr. Alessandro Riva, who runs Novartis's cancer R&D efforts.
PPHMBLING - Yes, I think the next few months should present some uplifting news events GLTU
Immunomodulatory Therapies (Nivolumab, MK 3475, Bavituximab)Studies performed by our group have shown that profound immunosuppression exists in patients with HCC compared with healthy normal subjects, and targeted depletion of subsets of immunosuppressive cells can partially restore antitumor immunity, suggesting that this may be a valid target in HCC.4,25 At least 2 anti-PD-1 antibodies (nivolumab and MK 3475) are being evaluated or will soon be evaluated in patients with HCC with careful characterization of the hepatitis status and biomarkers that are eagerly awaited. Phosphatidylserine (PS) is a phospholipid which, unlike other phospholipids that are randomly distributed in the plasma membrane of most cells, is actively maintained by an ATP-dependent. Phosphatidylserine externalizes during apoptosis and can trigger immunosuppressive signals that inhibit autoimmune antitumor responses. Bavituximab is a chimeric PS-targeting antibody that is well tolerated and is being evaluated in combination with sorafenib. It appears to have promising activity thus far. Renuka Iyer, MD, and Alexander Pomakov Published Online: October 6,
Today’s PPHM poster reiterates the powerful synergy of bavituximab with both Anti-CTLA-4 and Anti-PD-1: These combinations could really knock immuno oncology’s future out of the park.
Peregrine has numerous collaborations with these mAbs, and other immuno-oncology agents, as well. This extensive pre-clinical activity very likely points to a parallel amount of preliminary, or extended business that is not yet clearly visible to investors.
There is no question of the value of combining Anti-PS with these big pharma downstream immuno oncology mAbs, and because the collaborations are already occurring, there can be little doubt that serious negotiations could be intensifying. Does Peregrine do business with one Anti-PD-1 developer and not another? There is only one Anti-CTLA-4 out there, Yervoy, (BMY), and it is already FDA approved as the Standard of Care (SOC) in advanced melanoma. The value of today’s poster is to show investors and others exactly what the bavi synergy can do. If Yervoy, Anti-CTLA-4, was good enough to produce a SOC approval in advanced melanoma for BMY, then a bavi combination should push it a mile further ahead of where it already is. Is this phase1 an undeclared collaboration? It’s very intriguing!
So, Peregrine is already running a bavi plus Yervoy phase1 trial in advanced melanoma. Those here who read and understand the data in the pre-clinical studies “know” that the results from the bavi plus Yervoy phase1 are going to be spectacular.
There are FDA pathways to acceleration when there are “spectacular” results in early stage trials. No doubt there will be the usual bavituximab safety!
I think we’re cooking on all burners now. Peregrine is pushing forward a “hockey stick” execution of the phase3 NSCLC trial that should provide an FDA approval of bavituximab.
Because of the bavituximab synergy with other medical agents, and the broad spectrum applicability it has through it’s cancer common PS target, bavi should eventually .....
ver1tech disappointing commentary - onedumbwook has a point about "Shout-Down Crew" work for Icarus Consultants.